NervGen Pharma Corp
XTSX:NGEN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
NervGen Pharma Corp
Operating Income
NervGen Pharma Corp
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
NervGen Pharma Corp
XTSX:NGEN
|
Operating Income
-CA$25.5m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Bausch Health Companies Inc
TSX:BHC
|
Operating Income
$2.2B
|
CAGR 3-Years
16%
|
CAGR 5-Years
11%
|
CAGR 10-Years
0%
|
|
|
Canopy Growth Corp
TSX:WEED
|
Operating Income
-CA$52.8m
|
CAGR 3-Years
57%
|
CAGR 5-Years
42%
|
CAGR 10-Years
-9%
|
|
|
Cronos Group Inc
TSX:CRON
|
Operating Income
-$14.6m
|
CAGR 3-Years
48%
|
CAGR 5-Years
39%
|
CAGR 10-Years
-23%
|
|
|
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
|
Operating Income
-$151.2m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-123%
|
|
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
Operating Income
CA$5.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
NervGen Pharma Corp
Glance View
NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2019-03-13. The firm is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of nervous system injury due to trauma or disease as a result of underlying inflammation and/or neurodegeneration. The firm is advancing its lead compound, NVG-291, which is for the treatment of multiple sclerosis (MS), spinal cord injury (SCI) and Alzheimer’s disease. The firm has two wholly owned subsidiaries are NervGen US Inc. and NervGen Australia Pty Ltd.
See Also
What is NervGen Pharma Corp's Operating Income?
Operating Income
-25.5m
CAD
Based on the financial report for Sep 30, 2025, NervGen Pharma Corp's Operating Income amounts to -25.5m CAD.
What is NervGen Pharma Corp's Operating Income growth rate?
Operating Income CAGR 5Y
-21%
Over the last year, the Operating Income growth was -11%. The average annual Operating Income growth rates for NervGen Pharma Corp have been -7% over the past three years , -21% over the past five years .
